UWA-101

UWA-101 is a synthetic compound that is part of the benzofuran class of psychoactive drugs. It is known for its serotonin-related effects and is often used in scientific research.

History

UWA-101 was first synthesized and studied by a team of researchers at the University of Western Australia (UWA), from which it derives its name. The compound was developed as part of a broader effort to understand the role of serotonin in the brain and how it can be manipulated for therapeutic purposes.

Chemistry

UWA-101 is a benzofuran compound, which means it contains a fused benzene and furan ring. It is structurally similar to other psychoactive drugs such as MDMA and 5-APB, but it differs in that it has a methoxy group at the 5-position of the benzofuran ring.

Pharmacology

UWA-101 acts primarily as a serotonin releasing agent (SRA), meaning it promotes the release of serotonin in the brain. This can lead to a variety of effects, including feelings of euphoria, increased sociability, and altered perception. However, the exact effects can vary greatly depending on the dose and individual user.

Research and Potential Uses

Research on UWA-101 is still in its early stages, but it has shown promise in several areas. For example, it has been used to study the role of serotonin in mood disorders such as depression and anxiety. It has also been used in research on neurodegenerative diseases like Parkinson's disease and Alzheimer's disease, as these conditions are thought to involve dysregulation of the serotonin system.

Legal Status

The legal status of UWA-101 varies by country. In some jurisdictions, it is classified as a controlled substance due to its structural similarity to other psychoactive drugs. However, in many places, it is legal to possess and use for research purposes.

See Also

• Serotonin releasing agent
• Benzofuran
• Psychoactive drug

‎